AirSculpt Technologies (AIRS) is back in focus after reporting Q2 2026 results and reaffirming full year revenue guidance at the lower end of its US$151 million to US$157 million range.

The Q2 2026 update and guidance reaffirmation come after a sharp reset in AirSculpt Technologies' share price, with the stock falling 45.11% on a 1 day share price return and leaving the 1 year total shareholder return down 58.02%. However, the year to date share price return remains positive at 48.65%, which suggests recent momentum has faded after an earlier rebound.

If this kind of volatility has you looking beyond a single healthcare name, it could be a good moment to broaden your research and uncover 43 healthcare AI stocks

After such a sharp reset, AirSculpt Technologies now trades at a steep discount to the average analyst price target. Is the market being too harsh on a loss making specialty healthcare stock, or just realistic about the risks?

Most Popular Narrative: 56% Undervalued

On the most followed narrative, AirSculpt Technologies screens as materially undervalued, with a fair value of $6.25 against a last close of $2.75. This frames the recent sell off in a very different light.

Rising GLP-1 usage is creating a large, dedicated pool of patients with loose skin and residual contour issues. AirSculpt's early move into skin tightening and excision procedures positions it to capture incremental procedure volume and lift top line revenue.

Curious how a loss making healthcare stock arrives at that higher fair value? The narrative leans on modest revenue growth, meaningfully stronger margins and a premium future earnings multiple. The full story connects those assumptions into one tight valuation bridge that is not obvious from the headline share price collapse.

Result: Fair Value of $6.25 (UNDERVALUED)

However, the AirSculpt Technologies narrative also depends on consumer spending for elective procedures and assumes that marketing efforts and cost controls will offset potential pressure on margins and financing risk.

Another View: SWS DCF Model Flags Overvaluation

The analyst narrative paints AirSculpt Technologies as 56% undervalued, yet the SWS DCF model tells a different story. On that measure, AirSculpt trades above an estimated future cash flow value of about $0.40 per share, which points to valuation risk rather than a clear discount. Which set of assumptions do you find more realistic?

For a closer look at how this cash flow view is built and what would need to change for the DCF output to move closer to the analyst target, Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out AirSculpt Technologies for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment on AirSculpt Technologies clearly split between risk and reward, this is a moment to move quickly, review the underlying data, and decide where you stand. To weigh both sides of the argument in one place, start with the 1 key reward and 2 important warning signs.

Looking for more investment ideas beyond AirSculpt Technologies?

If AirSculpt Technologies has sharpened your focus on risk and reward, do not stop here. Broaden your watchlist now so you are not reacting after the next big move.

• Target growing profits with strong balance sheets by scanning companies in the solid balance sheet and fundamentals stocks screener (48 results).
• Spot potential value opportunities before the crowd notices through the screener containing 21 high quality undiscovered gems.
• Strengthen your income focus by reviewing companies in the 9 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.